Νορβηγία - Νορβηγικά - Statens legemiddelverk

fresenius - natriumklorid / kaliumklorid / natriumhydrogenkarbonat / kalsiumklorid / magnesiumkloridheksahydrat / glukosemonohydrat - hemodialyse-/hemofiltreringsvæske

Νορβηγία - Νορβηγικά - Statens legemiddelverk

fresenius - natriumklorid / kaliumklorid / natriumhydrogenkarbonat / kalsiumklorid / magnesiumkloridheksahydrat / glukosemonohydrat - hemodialyse-/hemofiltreringsvæske

Νορβηγία - Νορβηγικά - Statens legemiddelverk

fresenius - natriumklorid / natriumhydrogenkarbonat / kalsiumklorid / magnesiumkloridheksahydrat / glukosemonohydrat - hemodialyse-/hemofiltreringsvæske

Νορβηγία - Νορβηγικά - Statens legemiddelverk

fresenius kabi norge as - halden - natriumklorid - infusjonsvæske, oppløsning - 9 mg/ ml

Νορβηγία - Νορβηγικά - Statens legemiddelverk

farmagon - telmisartan / hydroklortiazid - tablett - 80 mg / 12.5 mg

Νορβηγία - Νορβηγικά - Statens legemiddelverk

fresenius kabi norge as - vorikonazol - pulver til infusjonsvæske, oppløsning - 200 mg

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - multippelt myelom - antineoplastiske midler - bortezomib som monoterapi eller i kombinasjon med pegylated liposomal doxorubicin eller deksametason er indisert for behandling av voksne pasienter med progressiv multippel myelom som har mottatt minst 1 før behandling, og som har gjennomgått eller er uegnet for haematopoietic stilk cellen transplantasjon. bortezomib i kombinasjon med melphalan og prednison er indisert for behandling av voksne pasienter med tidligere ubehandlet myelomatose som ikke er kvalifisert for høydose kjemoterapi med haematopoietic stilk cellen transplantasjon. bortezomib i kombinasjon med deksametason, eller med dexamethasone og thalidomid, er indikert for induksjon behandling av voksne pasienter med tidligere ubehandlet myelomatose som er kvalifisert for høydose kjemoterapi med haematopoietic stilk cellen transplantasjon. bortezomib i kombinasjon med rituximab, cyklofosfamid, doxorubicin og prednison er indisert for behandling av voksne pasienter med tidligere ubehandlet mantelen celle lymfom som er uegnet for haematopoietic stilk cellen transplantasjon.

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.